lecanemab

Lecanemab (Leqembi)

Introduction

Lecanemab (brand name Leqembi; development code BAN2401) is a humanized IgG1 monoclonal antibody therapeutic developed by Eisai Co., Ltd. in partnership with Biogen Inc. for the treatment of early Alzheimer's disease (AD). Approved by the U.S. Food and Drug Administration (FDA) in January 2023, lecanemab represents a landmark achievement as the first amyloid-targeting antibody to demonstrate clinically meaningful slowing of cognitive decline in a Phase III clinical trial[@van2023].

This entity profile provides a comprehensive overview of lecanemab as a therapeutic entity within the NeuroWiki knowledge base, covering its molecular characteristics, mechanism of action, clinical development, and position within the landscape of Alzheimer's disease therapeutics. For detailed clinical trial data, efficacy analyses, and safety profiles, refer to the dedicated therapeutics page: [Lecanemab (Leqembi) — Therapeutics](/therapeutics/lecanemab).

Molecular Characteristics

Antibody Class and Structure

Lecanemab is a humanized IgG1 monoclonal antibody engineered for optimal binding to amyloid-beta (Aβ) protofibrils. The antibody was developed using Ei's proprietary platform, which employs a combination of phage display and immunization strategies to identify antibodies with specific binding profiles[@honma2023].

Key molecular properties:

Lecanemab (Leqembi)

Introduction

Lecanemab (brand name Leqembi; development code BAN2401) is a humanized IgG1 monoclonal antibody therapeutic developed by Eisai Co., Ltd. in partnership with Biogen Inc. for the treatment of early Alzheimer's disease (AD). Approved by the U.S. Food and Drug Administration (FDA) in January 2023, lecanemab represents a landmark achievement as the first amyloid-targeting antibody to demonstrate clinically meaningful slowing of cognitive decline in a Phase III clinical trial[@van2023].

This entity profile provides a comprehensive overview of lecanemab as a therapeutic entity within the NeuroWiki knowledge base, covering its molecular characteristics, mechanism of action, clinical development, and position within the landscape of Alzheimer's disease therapeutics. For detailed clinical trial data, efficacy analyses, and safety profiles, refer to the dedicated therapeutics page: [Lecanemab (Leqembi) — Therapeutics](/therapeutics/lecanemab).

Molecular Characteristics

Antibody Class and Structure

Lecanemab is a humanized IgG1 monoclonal antibody engineered for optimal binding to amyloid-beta (Aβ) protofibrils. The antibody was developed using Ei's proprietary platform, which employs a combination of phage display and immunization strategies to identify antibodies with specific binding profiles[@honma2023].

Key molecular properties:

| Property | Value |
|----------|-------|
| Antibody type | Humanized IgG1 |
| Molecular weight | ~150 kDa |
| Target | Aβ protofibrils (soluble oligomers) |
| Affinity (Kd) for protofibrils | ~10⁻¹⁰ M |
| Affinity (Kd) for monomers | Significantly lower |
| Fc region | Native (not engineered) |

Target Specificity

One of lecanemab's distinguishing features is its preferential binding to soluble Aβ protofibrils rather than monomers or mature amyloid plaques. Protofibrils are intermediate-length Aβ aggregates (approximately 100-600 kDa) that have been identified as the most toxic form of Aβ in experimental models. Research has demonstrated that protofibrils are 10-100 times more toxic per molecule than monomeric Aβ, making them an attractive therapeutic target[@mcdade2022].

The selectivity for protofibrils differentiates lecanemab from other anti-amyloid antibodies:

• Aducanumab: Binds primarily to monomeric and plaque Aβ
• Donanemab: Targets Aβ plaques (N-terminal truncation modifications)
• Lecanemab: Prefers soluble protofibrils over plaques

Mechanism of Action

Primary Mechanisms

Lecanemab exerts its therapeutic effects through multiple complementary mechanisms:

1. Direct Neutralization of Toxic Protofibrils
By binding to soluble Aβ protofibrils, lecanemab neutralizes their neurotoxicity and prevents their interaction with neurons, synapses, and glia. This prevents downstream downstream signaling events that lead to synaptic dysfunction and neuronal death.

2. Fcγ Receptor-Mediated Clearance
The antibody-opsonized Aβ complexes engage Fcγ receptors on microglia, triggering microglial phagocytosis and lysosomal degradation. This represents the primary clearance mechanism for lecanemab-bound amyloid[@logovinsky2024].

3. Peripheral Sink Effect
Binding of lecanemab to plasma Aβ creates a concentration gradient that promotes efflux of Aβ from the brain parenchyma into the peripheral circulation. This "peripheral sink" mechanism contributes to overall amyloid reduction.

4. Plaque Destabilization
Evidence suggests lecanemab may also destabilize existing amyloid plaques, facilitating their conversion to soluble aggregates that can be cleared by the mechanisms described above.

Relationship to Microglial Function

Lecanemab's mechanism is intimately connected to microglial biology. The antibody's efficacy depends on functional microglial phagocytosis, which involves several microglial receptors and pathways:

• TREM2: Triggering receptor on myeloid cells 2, essential for microglial phagocytosis
• CD36: Scavenger receptor facilitating Aβ uptake
• Fcγ receptors: Mediate antibody-dependent cellular phagocytosis (ADCP)
• Complement system: May provide additional opsonization for microglial clearance

Clinical Development History

Preclinical Development (2007-2014)

Lecanemab was discovered through a collaboration between Eisai and BioArctic. Early preclinical studies demonstrated:

• Selective binding to Aβ protofibrils in vitro
• Reduction of brain amyloid in mouse models
• Favorable pharmacokinetic properties in non-human primates
• No concerning safety signals in toxicology studies

Phase I Studies (2014-2016)

Phase I clinical trials established:

• Safety and tolerability in healthy volunteers and early AD patients
• Dose-proportional pharmacokinetics
• Dose-dependent reduction in CSF Aβ42
• Optimal dosing: 10 mg/kg biweekly

Phase II Study 201 (2016-2019)

The Phase IIb study enrolled 856 patients with early AD (MCI due to AD or mild AD dementia)[@mcdade2022]:

• Primary endpoint: AD Composite Score (ADCOMS) at 18 months
• Results: Dose-dependent clinical and biomarker effects
• Key finding: Highest dose (10 mg/kg biweekly) showed slowest clinical decline
• Established: Optimal dosing regimen for Phase III

Phase III Clarity-AD (2019-2022)

The pivotal Phase III Clarity-AD trial enrolled 1,795 patients with early AD across 233 sites in North America, Europe, and Asia[@van2023]:

• Primary endpoint: Change in CDR-Sum of Boxes (CDR-SB) at 18 months
• Result: 27% slowing of clinical decline (0.45 CDR-SB points vs. placebo)
• Amyloid reduction: Centiloid reduction from 53 to 10 (~81% reduction)
• Biomarker effects: Significant reductions in CSF p-tau181 and t-tau

Post-Approval Development (2023-Present)

Following FDA approval, development continues with:

• Clarity-OLE: Open-label extension studying long-term safety and efficacy
• AHEAD 3-45: Prevention trial in preclinical AD populations
• DIAN-TU: Targeting dominantly inherited Alzheimer's disease
• Real-world studies: Observational studies in clinical practice settings[@feinstein2024]

Regulatory Status

Global Approvals

| Region | Status | Date |
|--------|--------|------|
| United States | Full FDA approval | January 2023 |
| Japan | Approved | January 2023 |
| South Korea | Approved | May 2023 |
| China | Approved | October 2023 |
| Australia | Approved | December 2023 |
| United Kingdom | Under review | - |
| European Union | Under review | - |

Indication

Lecanemab is indicated for the treatment of early Alzheimer's disease, specifically:

• Mild cognitive impairment (MCI) due to Alzheimer's disease
• Mild Alzheimer's disease dementia

Position in Alzheimer's Disease Therapeutics

Comparison with Other Anti-Amyloid Antibodies

| Feature | Lecanemab | Donanemab | Aducanumab |
|---------|-----------|-----------|------------|
| Target | Protofibrils | Plaques | Monomers/plaques |
| Dosing | 10 mg/kg biweekly | Weight-based | 10 mg/kg monthly |
| Amyloid reduction | ~81% | ~70% | ~60% |
| CDR-SB benefit | 0.45 | 0.70 | 0.39 |
| ARIA-E rate | 12.6% | 24% | 35% |

Therapeutic Positioning

Lecanemab occupies a unique position in the AD therapeutic landscape:

Relationship to Disease-Modifying Therapy Paradigm

Lecanemab's approval validates the amyloid cascade hypothesis and establishes disease-modifying therapy as the standard for AD treatment. The demonstration that amyloid removal correlates with clinical benefit has accelerated development of additional anti-amyloid and anti-tau therapeutics.

Therapeutic Considerations

Patient Selection Criteria

Optimal candidates for lecanemab therapy meet the following criteria:

• Clinical: Early AD (MCI or mild dementia)
• Biomarker: Confirmed amyloid pathology
• Cognitive: CDR 0.5-1.0, MMSE 22-30
• Functional: Independent or minimally assisted ADL
• Safety: No contraindication to MRI monitoring

Monitoring Requirements

Patients receiving lecanemab require regular monitoring:

• Baseline MRI: Within 6 months before first infusion
• Follow-up MRI: Week 12, Week 24, then annually
• APOE genotyping: Informs ARIA risk assessment
• Clinical assessments: Regular cognitive testing

Risk Factors for ARIA

| Risk Factor | Impact |
|-------------|--------|
| APOE ε4 homozygosity | Highest ARIA risk |
| APOE ε4 heterozygosity | Moderate ARIA risk |
| Prior cerebral microhemorrhages | Increased risk |
| Anticoagulant use | Increased hemorrhage risk |

Cross-Links to NeuroWiki Entities

Related Proteins and Pathways

• [Amyloid-Beta](/proteins/amyloid-beta) — Primary therapeutic target
• [Tau Protein](/proteins/tau) — Downstream pathology
• [APOE](/proteins/apoe-protein) — Genetic risk modifier
• [TREM2](/genes/trem2) — Microglial receptor for amyloid clearance

Related Diseases and Conditions

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Target indication
• [MCI (Mild Cognitive Impairment)](diseases/mci) — Earlier disease stage

Related Mechanisms

• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis) — Foundational mechanism
• [Microglial Phagocytosis](/mechanisms/microglial-phagocytosis) — Clearance pathway
• [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway) — Related pathway
• [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers) — Inflammatory consequences

Related Therapeutics

• [Donanemab (Kisunla) — Entity](/entities/donanemab) — Alternative anti-amyloid antibody
• [Aducanumab (Aduhelm) — Entity](/entities/aducanumab) — Earlier anti-amyloid antibody
• [Lecanemab — Therapeutics](/therapeutics/lecanemab) — Detailed clinical data

Key Clinical Trials

| Trial | Phase | Population | Status | Key Results |
|-------|-------|------------|--------|-------------|
| Study 201 | IIb | Early AD (n=856) | Complete | Dose-dependent efficacy |
| Clarity-AD | III | Early AD (n=1,795) | Complete | Primary endpoint met |
| Clarity-OLE | III | Previous lecanemab pts | Ongoing | Long-term safety/efficacy |
| AHEAD 3-45 | III | Preclinical AD | Recruiting | Prevention trial |

Research Gaps and Future Directions

Unanswered Questions

Despite lecanemab's approval, several important questions remain:

Ongoing Research

Active research areas include:

• Tau combination trials: Studying lecanemab with anti-tau antibodies
• Prevention trials: Earlier intervention in preclinical populations
• Biomarker development: Identifying predictors of response
• Delivery optimization: Exploring subcutaneous administration

References

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta Protein](/proteins/amyloid-beta)
• [Donanemab (Kisunla) — Entity](/entities/donanemab)
• [Lecanemab — Therapeutics](/therapeutics/lecanemab)
• [Anti-Amyloid Immunotherapy](/mechanisms/amyloid-immunotherapy-pathway)
• [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway)
• [Microglia — Cell Type](/cell-types/microglia)

External Links

• [Leqembi Official Website](https://www.leqembi.com)
• [ClinicalTrials.gov: Lecanemab](https://clinicaltrials.gov/search?term=Lecanemab)
• [FDA Approval Announcement](https://www.fda.gov/drugs/news-events-human-drug-alerts/fda-grants-accelerated-approval-alzheimers-disease-treatment-leqembi-lecanemab)
• [Eisai Product Information](https://www.eisai.com)
• [Biogen Alzheimer's Disease Portfolio](https://www.biogen.com)

Allen Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — Brain gene expression data for targets relevant to AD pathogenesis
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Single-cell expression data for microglia and neurons

Pathway Diagram

Key molecular relationships involving lecanemab from the SciDEX knowledge graph: